BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma

Phase 1

Withdrawn

Conditions: Stage III or IV Melanoma

Interventions: Biological: BMS-936559 (Anti-PD-L1)

First Posted Date: 2011-10-19

Last Posted Date: 2011-12-13

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT01455103

Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: BMS-708163 (Gamma-Secretase Inhibitor)
Drug: Placebo matching BMS-708163

First Posted Date: 2011-10-18

Last Posted Date: 2011-11-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 116

Registration Number: NCT01454115

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Drug: Gemcitabine
Drug: Paclitaxel
Drug: Bevacizumab
Drug: Erlotinib
Drug: Cisplatin
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2011-10-18

Last Posted Date: 2021-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 472

Registration Number: NCT01454102

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇨🇦
Local Institution, Toronto, Ontario, Canada

and more 7 locations

Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy

Phase 1

Withdrawn

Conditions: Non-Hodgkin's Lymphoma
Hodgkin Lymphoma
Multiple Myeloma
Chronic Myelogenous Leukemia

Interventions: Biological: BMS-936559 (Anti PD-L1)

First Posted Date: 2011-10-14

Last Posted Date: 2012-02-23

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT01452334

Comparative Tolerability of Protease Inhibitors

Completed

Conditions: HIV

First Posted Date: 2011-10-12

Last Posted Date: 2012-12-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 26000

Registration Number: NCT01450618

Korean Post-marketing Surveillance for Reyataz®

Completed

Conditions: HIV-1

Interventions: Drug: No Intervention

First Posted Date: 2011-10-12

Last Posted Date: 2016-04-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 601

Registration Number: NCT01450605

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Phase 3

Completed

Conditions: Small Cell Lung Carcinoma

Interventions: Biological: Placebo matching Ipilimumab
Biological: Ipilimumab
Drug: Etoposide
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2011-10-12

Last Posted Date: 2020-07-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1351

Registration Number: NCT01450761

Locations: 🇺🇸
University Of Texas, M. D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University Hospitals, Cleveland, Ohio, United States
🇺🇸
Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States

and more 40 locations

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: BMS-790052 (NS5A Replication Complex Inhibitor)
Drug: Placebo matching BMS-790052
Drug: Pegylated-interferon alfa 2a
Drug: Ribavirin

First Posted Date: 2011-10-07

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 152

Registration Number: NCT01448044

Locations: 🇺🇸
University Gastroenterology, Providence, Rhode Island, United States
🇺🇸
Metropolitan Research, Annandale, Virginia, United States
🇬🇧
Local Institution, London, Greater London, United Kingdom

and more 2 locations

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Phase 3

Withdrawn

Conditions: Hepatitis C Virus (HCV)

Interventions: Biological: Pegylated Interferon Lambda
Biological: Pegylated Interferon Alfa-2a
Drug: Ribavirin

First Posted Date: 2011-10-06

Last Posted Date: 2012-02-03

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT01447394

Locations: 🇬🇧
Local Institution, Birmingham, West Midlands, United Kingdom

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: 100 mg INX-08189 BID Fasted
Drug: 100 mg INX-08189 QD
Drug: 100 mg INX-08189 with low-fat meal
Drug: 200 mg INX-08189 Fasted
Drug: Placebo QD Fasted
Drug: Placebo QD
Drug: Placebo with low-fat meal
Drug: Placebo BID Fasted
Drug: ribavirin

First Posted Date: 2011-10-04

Last Posted Date: 2016-06-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 50

Registration Number: NCT01445795

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy